Cognition Therapeutics Receives $3.3 Million NIA Grant to Conduct qEEG Study of Elayta™ with World-Leading Alzheimer’s Biomarker Experts
09 juil. 2019 08h02 HE
|
Cognition Therapeutics, Inc.
PITTSBURGH, July 09, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
Cognition Therapeutics Expands Clinical Expertise on Medical Advisory Board with Addition of Drs. Mary Sano and Philip Scheltens
05 avr. 2019 08h02 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, April 05, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
Cognition Therapeutics Elects Lisa Ricciardi to its Board of Directors
26 mars 2019 09h51 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, March 26, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
Cognition Therapeutics Receives European Patent Covering its Alzheimer's Disease Candidate, Elayta™
21 févr. 2019 08h03 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
Cognition Therapeutics Expands Industry-Leading Expertise in Research and Clinical Use of Biomarkers of Alzheimer’s Disease
27 nov. 2018 08h03 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
Cognition Therapeutics Initiates Patient Dosing in Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer's Disease
08 nov. 2018 08h03 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other...
Cognition Therapeutics Presents Additional Elayta™ Clinical Results during Alzheimer's Association International Conference (AAIC) Symposium Session
23 juil. 2018 14h19 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, July 23, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurodegenerative disorders, today...
Cognition Therapeutics Initiates NIA-Funded SPARC Study of Elayta™ to Assess Changes in Synaptic Density and Cognitive Performance in Alzheimer's Disease
18 juin 2018 08h03 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, June 18, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurocognitive disorders, today...
Cognition Therapeutics Receives $6.6M in NIA Grants for Two Studies of Elayta™ to Expand Understanding of Synaptoprotective Mechanism of Action
22 mai 2018 08h02 HE
|
Cognition Therapeutics, Inc.
PITTSBURGH, May 22, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at the Annual ASENT Meeting
06 mars 2018 14h04 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, March 06, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...